Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | GAPDH | P04406 | 2/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HRAS | P01112 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10620690 | 0.90 | MEN1 (0.54) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL11320454 | 0.89 | MEN1 (0.53) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL15962206 | 0.85 | P2RX3 (0.40) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL27527014 | 0.81 | MEN1 (0.51) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL20078065 | 0.80 | MEN1 (0.58) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL15702572 | 0.80 | MEN1 (0.58) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL15705224 | 0.80 | MEN1 (0.58) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL2295858 | 0.80 | MEN1 (0.58) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL13376162 | 0.80 | MEN1 (0.58) | MEN1USP2POLBKMT2ACA1 | |
| SCHEMBL13019185 | 0.80 | MEN1 (0.58) | MEN1USP2POLBKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186369-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | INDENIX PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8742101-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2006-10-26 | — | — | US | disclosed |
| EP-1227103-B1 | Ring-expanded nucleosides and nucleotides | NABI (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2004-04-22 | — | — | US | disclosed |
| US-6677310-B1 | ANTICARCINOGENIC AGENTS; BACTERICIDES, FUNGICIDES, PARASITICIDES; VIRICIDES AGAINST HEPATITIS, EPSTEIN-BARR, CYTOMEGALO AND HUMAN IMMUNODEFICIENCY VIRUS | NABI | 2004-01-13 | — | — | US | disclosed |
| US-6069132-A | PYRIMIDOPHOSOHAZOLE RING SYSTEM OF GIVEN STRUCTURE, THE TRIVALENT PHOSPHORUS OF THE RING SUBSTITUTED WITH VARIOUS GROUPS; NEW CLASS OF PHOSPHORUS CONTAINING HETEROCYCLES WITH APPLICATION IN MEDICAL, AGRICULTURAL AND INDUSTRIAL USE | ARONEX PHARMACEUTICALS, INC. | 2000-05-30 | — | — | US | disclosed |
| US-5843912-A | Ring-expanded nucleosides and nucleotides | UNIVERSY OF MARYLAND (US) | 1998-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | MEN1 3963/4885USP2 2280/4885POLB 1667/4885 |
| US-20060241065-A1 | Ring-expanded nucleosides and nucleotides | PNP, UMPS, ADA | MEN1 2103/4885USP2 4113/4885POLB 433/4885 |
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | MEN1 3963/4885USP2 2280/4885POLB 1667/4885 |
| US-20040077564-A1 | Ring expanded nucleosides and nucleotides | PNP, PAICS, UMPS | MEN1 2287/4885USP2 4306/4885POLB 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.